

### Sales revenues for March 2018

**Sofia, Bulgaria**, April 5, 2018 - **Sopharma AD** (3JR: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for March 2018 the Company recorded a decrease of sales revenues of 10% compared to the same month of 2017, including 1% increase of domestic sales and a decrease of 19% of export sales.

For the first three months of this year, revenues from sales of products decreased by 3% compared to the same period of 2017, including 0.5% increase of domestic sales and 6% decrease of export sales.



**Pelagia Viatcheva**  
**Investor Relations Director,**  
**Sopharma AD**

### Information about the company

#### Sopharma AD

85 years tradition and modern approach – modern production, European quality standards, corporate social responsibility. Sopharma has an active and crucial role in raising standards of everyday life, in making people healthier, happier and safer. Sopharma AD continuously invests in technologies, innovation, research and science. We establish a constant and effective dialogue with all the actors in the pharmaceutical industry that contribute to the improvement of the health care system.

The company produces and markets medicinal substances and dosage forms; conducts research, engineering and implementation activities in the field of phytochemistry, chemistry and pharmaceuticals. Sopharma AD provides services related to production, as well as to ancillary and service activities.

The Company has a portfolio of more than 210 products: mainly generics and 15 original products, of which 12 products are phyto-based.

#### Sopharma Group

Sopharma Group is a vertically integrated healthcare business that operates in important sectors such as pharmaceuticals production, hospital supplies, pharmaceutical distribution (GDP standardized) and others. Sopharma and its production subsidiaries have 12 pharmaceutical plants in Bulgaria, complying with EU requirements – GMP and a factory in Ukraine certified by local authorities.